Viagra vs Hezkue for Erectile Dysfunction
Trial Summary
What is the purpose of this trial?
The objective of this phase 1, open-label, single-center, two-way crossover trial is to evaluate the pharmacokinetics (PK), safety, and tolerability of 100 mg ASP-001 oral liquid suspension versus 100 mg Viagra (sildenafil citrate) tablets in fasted, healthy male volunteers
Eligibility Criteria
This trial is for healthy, fasted male participants who want to help compare the effects of two erectile dysfunction treatments: Viagra and a new drug called Hezkue (ASP-001).Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment Period I
Participants receive either 100 mg of ASP-001 or 100 mg of Viagra
Washout
A washout period between treatment periods
Treatment Period II
Participants receive the alternate treatment (100 mg of ASP-001 or 100 mg of Viagra)
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- ASP-001
- Viagra
Find a Clinic Near You
Who Is Running the Clinical Trial?
Aspargo Labs, Inc
Lead Sponsor